# MDM4

Source: https://onco.cc/targets/mdm4/  
OnCo record `mdm4` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

MDM4 (MDM4 regulator of p53) is a gene. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Skin cancer, Breast cancer, Prostate cancer and 1 more.

## Summary

Contributes to p53/TP53 regulation. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding their transcriptional activation domains. Inhibits degradation of MDM2.

CIViC holds 2 clinical evidence items and 0 assertions across 2 variants, naming Nivolumab, Pembrolizumab and Atezolizumab. Open Targets scores its association with cancer at 0.75 (direct and indirect evidence; datatypes affected pathway 0.57, literature 0.99, genetic association 0.60, somatic mutation 0.97, animal model 0.49).

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: MDM4 regulator of p53
- Tags: cancer-genes-wave
- Symbol: MDM4
- Class: other
- Biology: Contributes to p53/TP53 regulation. Inhibits p53/TP53- and p73/TP73-mediated cell cycle arrest and apoptosis by binding their transcriptional activation domains. Inhibits degradation of MDM2. Can reverse MDM2-targeted degradation of TP53 while maintaining suppression of TP53 transactivation and apoptotic functions. Location: Nucleus; Cytoplasm (UniProt). Locus 1q32.1 (HGNC).
- Where found: Skin cancer: Open Targets association 0.56 with skin cancer (MONDO_0002898); Breast cancer: Open Targets association 0.55 with breast cancer (MONDO_0007254); Prostate cancer: Open Targets association 0.55 with prostate cancer (MONDO_0008315); Melanoma: Open Targets association 0.59 with melanoma (MONDO_0005105)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 3 therapies; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:6974: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6974
- UniProt O15151: https://www.uniprot.org/uniprotkb/O15151/entry
- NCBI Gene 4194: https://www.ncbi.nlm.nih.gov/gene/4194
- Ensembl ENSG00000198625: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198625

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/), [Melanoma](https://onco.cc/cancers/melanoma/), [Prostate cancer](https://onco.cc/cancers/prostate/), [Skin cancer (all types)](https://onco.cc/cancers/skin-cancer/)
- pathways: [The p53 network (guardian of the genome)](https://onco.cc/pathways/p53-mdm2-axis/)

---
JSON: https://onco.cc/api/v1/entities/mdm4.json